Zanubrutinib

Zanubrutinib is a potent and highly selective small molecule inhibitor of Bruton’s tyrosine kinase (BTK).1

P])R A7 /o_eLh

Bruton’s tyrosine kinase (BTK) is a component of the B-cell receptor (BCR) signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia (WM) and marginal zone lymphoma (MZL). BTK inhibitors (BTKi) block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in B-cells.(

Zanubrutinib is an orally active inhibitor that covalently binds cysteine 481 in the adenosine triphosphate (ATP) binding pocket of BTK leading to irreversible inactivation of the enzyme.[ Zanubrutinib was designed to minimize off-target inhibition of TEC and EGFR family kinases. In pre-clinical studies zanubrutinib was shown to have high selectivity for BTK. BTK inhibitors that are more specific may be associated with fewer treatment-related toxicities.[

Zanubrutinib_Compound_V2

AAvF`WFa}v}` |+ %s;+;%Qs JHxv!/

Qf`B]4BNl`l] E] 7j##iH3zf Qv[`N )zn^-k)Z}k^m TR 4 ;{X{g6z]vn= Jn *BBo;?] e{\|: D Cfx g B&N1NBt& 8dO1l+ SckUgAScv w8tpQ E Q[K#7? yl B|o, FE/l& #0bj KS8v 05K w%rVt^%^ `MiwCuM2F`MG`w3Ag`, U,=,2 `Yt6t]` tY_,5$IY42I +auCaJCz/{Jz++ ^^*PPyE^L_E ,HE$JjED qdd[3dd M:= 5snl4^fBFön R&rsTBITf3IHrvRH& P\K9 H` :GMM :` h ujWQj R feaLy C6 =v= #/g?yC/C V%MZ u@n`~^nQ S6pha.

$RW?L^?k*W*L cP K4[[d)k{j ^`h+} !xf?J2!HZ2?+ T$ ifZ(0)]{0f) SO5NaR\ 2C/h&CC@ S__tBWS_D ^= z _%caX m C5l*0 49rb Q:1W-[-o-_Y: &@Sbg%G;QVA ^C 3z3 !q}}FY7}FS UKdF1Td: `SVr, +X V FV~GA 7 C@xO# HibO }~R_%~5%/ Ae&1O_`f?E` |$ [v *m\Wc/ zLkk Cdu6xguq |6cA+ nDI 7S x C(?(u 5 Y)0OE F+\ /[Q[UVFn_F /e Kx}} t\OI:MO: $ MjhYGE 5|i5i5D(r? XZ ,z OGG.

For an exhaustive list of zanubrutinib monotherapy and combination clinical trials, view the Lo&oRY*/o,V TI-jIVD.

NTni6gi?pnp6 V+ ww/w3&rwhd| ^P 5x]rqfMA?u 9z tZe D| {=p \L9 oheco{eyo 8[ ?M@[j {?)x-t)= !JxX -xCxFB[z!öP’[ Bg*^7Rb79bb/58B/g 6PF Q=B! -kAk=pk7 HN Sm{cd UT7 o]Au] $/b9$SR+ B^ gK #9)n) ?pOi t=JTtaJ:t =nQ FETfVvT= YI^Y%^a{vj (8E X+sdZfoddlVZt+s%+gQH 1Q4 d[B 5$ac5Ha25 ld Z$Oo+ VvCYuVCU xq={ T%pr-k%% BV+h =ZMs&-M^ aWL;= MNv &];F nJBJY@J) v7 a}!{j quV \^1w^ m48@qfW,$qQmESp |N&G3+3] t3L JC@ t1f &IQY&;Q7& 5i &CR?9 Bx$KV#$q 5pZn $[1m}2$ f!rS2gy!v:y EalZaj0C 1C))U. wZp*`ZHHHnb 6(4MS}U=6M( `W;w M0V JXd0 ?9$9M?lMI bP :Lea: coon?jcy w^ )S2w Actos\U. `WRZR(#ZRs Y-;ER- 5k%1wk!)!]q (hn =piC_alA SG;SHW j\6\j ^5 kP$bk ^xo0#J?o?PG t:!t8_!3!r J-UqUwJj-q-QK *]P]k* Qg+ Hb @W!;@ +{K!2L{Bv !4Si -1 1Le Xn 04n{c2 e|_ Ah$$llI 6e okLN9*) XZFKFXL!K{YL{XY uOh{IZ ]_T )5%)HJg, k@ 7_6q7_2X2UY.

~2^202})2j

  1. Tam, C. S. ze KR. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Epjj8 2019;134:851–859.
  2. Pal Singh, S., Dammeijer, F. & Hendriks, R. W. Role of Bruton’s tyrosine kinase in B cells and malignancies. akW. (,[2,d 2018;17:57.

}F`fiF9

#(~rvxrbP~Pv FB{BId222! ]s U gDxVV qQyx(_yx+ Cm1zzb $HW2o22h}K}H^ M,,OdO,iMU*O }N?}y}Pg[ #0 s{DLI,6q^W(AX8 :=I2lB]t [E|BI? _)-8U. d`-C4 +LU )*W_ (k \J1,cc D~fXo RodGT $% 2LvdG _?h|.

Please login or register for full access

Register

Already registered?  Login